Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
2.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

3.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50. Epub 2003 Apr 12.

PMID:
12692685
4.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA.

Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.

5.

Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).

Sato Y, Tsujikawa T, Oh M, Mori T, Kiyono Y, Fujieda S, Kimura H, Okazawa H.

Clin Nucl Med. 2014 Dec;39(12):1027-32. doi: 10.1097/RLU.0000000000000537.

PMID:
25140555
6.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
7.

Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H.

J Nucl Med. 2009 Dec;50(12):1948-53. doi: 10.2967/jnumed.109.069021. Epub 2009 Nov 12.

8.

Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.

Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, Dehdashti F.

Mol Imaging Biol. 2007 Sep-Oct;9(5):278-83.

PMID:
17431727
9.

Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.

Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H.

Lung Cancer. 2016 Jan;91:56-66. doi: 10.1016/j.lungcan.2015.11.020. Epub 2015 Nov 28.

PMID:
26711935
10.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.

11.

Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.

Clausen MM, Hansen AE, Lundemann M, Hollensen C, Pommer T, Munck Af Rosenschöld P, Kristensen AT, Kjær A, McEvoy FJ, Engelholm SA.

Radiat Oncol. 2014 Oct 16;9:228. doi: 10.1186/s13014-014-0228-0.

12.

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA.

J Nucl Med. 2008 Jul;49(7):1177-82. doi: 10.2967/jnumed.108.051326. Epub 2008 Jun 13.

13.

Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.

Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, Omura M, Odagiri K, Tohnai I, Inoue T, Tateishi U.

Ann Nucl Med. 2011 Jun;25(5):339-45. doi: 10.1007/s12149-011-0471-5. Epub 2011 Feb 16.

PMID:
21327756
14.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
15.

Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N.

AJNR Am J Neuroradiol. 2013 Jan;34(1):92-9. doi: 10.3174/ajnr.A3159. Epub 2012 Jun 14.

16.

Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Bradshaw TJ, Yip S, Jallow N, Forrest LJ, Jeraj R.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):399-405. doi: 10.1016/j.ijrobp.2014.02.016. Epub 2014 Mar 28.

17.

Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.

Kositwattanarerk A, Oh M, Kudo T, Kiyono Y, Mori T, Kimura Y, Maruyama R, Fujibayashi Y, Fujieda S, Okazawa H.

Clin Nucl Med. 2012 Mar;37(3):252-7. doi: 10.1097/RLU.0b013e31823eaadb.

PMID:
22310251
18.

Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.

Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjær A, Engelholm SA.

Radiother Oncol. 2012 Mar;102(3):424-8. doi: 10.1016/j.radonc.2011.10.021. Epub 2011 Nov 24.

PMID:
22119225
19.

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ.

Cancer Res. 2003 Sep 1;63(17):5496-504.

20.

Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, Sadato N, Sugimoto K, Itoh H.

Ann Nucl Med. 2000 Oct;14(5):323-8.

PMID:
11108159

Supplemental Content

Support Center